AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Sign up Log in

Poxel Report Publication Announcement 2016

Jun 14, 2016

1606_rf_2016-06-14_f56a3196-4978-4607-adab-77067dd54fa6.pdf

Report Publication Announcement

Open in viewer

Opens in your device viewer

Press Release

Poxel makes available to the Public its 2015 Reference Document

Lyon, France, June 14, 2016 – POXEL SA (Euronext – POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative drugs to treat type 2 diabetes, informs its shareholders and the financial community that its 2015 Registration Document was made available to the public and registered with the AMF as of June 13, 2016 under the number R. 16-053.

The document is available on the AMF website (www.amf-france.org) and on the website of the company (www.poxel.com) in the Investors section.

About Imeglimin

Imeglimin is the first in a new chemical class of oral anti-diabetic agents, the Glimins. Imeglimin acts on three main target organs involved in glucose homeostasis: the liver, muscle, and the pancreas. Imeglimin's unique mechanism of action targets the mitochondrial bioenergetics. This distinct mode of action compared to existing treatments for type 2 diabetes makes Imeglimin a prime candidate in monotherapy and to complement other treatments such as metformin or sitagliptin.

About Poxel

Poxel uses its development expertise in metabolism to advance a pipeline of drug candidates focused on the treatment of type 2 diabetes. We have successfully completed our Phase 2 trials for our first-in-class lead product, Imeglimin, which targets mitochondrial dysfunction, in the U.S. and EU and have entered Phase 2b clinical development in Japanese patients. We are advancing our second program, PXL770, a direct AMPK activator, which is in Phase 1 development. We intend to generate further growth through strategic partnerships and pipeline development. (Euronext: POXEL, www.poxel.com)

Contacts

Poxel SA Jonae R. Barnes Senior Vice President, Investor Relations and Public Relations [email protected] +1 617 818 2985